Alzheimer’s disease is a debilitating condition that takes a large toll on patients and their loved ones. Most available treatments ease the symptoms, but do not target the root cause of the disease or slow its progression. Only in the past year has there been the introduction of the first disease modifying therapies that offer new hope, however there is significant room for improvement.
By 2050, as many as 13 million people will be diagnosed with Alzheimer’s disease. The cost of providing care for them is estimated at more than one trillion dollars.
The need for new, innovative treatments is greater than ever.
In 2022, the Indiana Biosciences Research Institute (IBRI) joined the fight against Alzheimer’s disease. Our research aims to:
- Improve understanding of the underlying mechanisms that cause the disease.
- Discover new approaches to target the root cause of the disease. This includes Identifying novel therapies that could treat it in the early stages.
- Explore new frontiers of precision medicine for Alzheimer’s disease where we match each person with the treatment that will be most effective for their unique disease.